AMG 340 — Investigational Agent
T-Cell Engager · Phase 1 · Amgen
Mechanism of Action
A low-affinity CD3 x PSMA bispecific T-cell engager designed to redirect cytotoxic T cells to PSMA-expressing prostate cancer cells while attenuating cytokine release through reduced CD3 affinity.
Investigational Indications
- Metastatic castration-resistant prostate cancer